Secondary Central Nervous System Lymphoma

Secondary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 22%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05485753	A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)	active not recruiting	Phase 1 / Phase 2	7	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 26, 2025	clinicaltrials

Data updated 22 days agoSource updated Sep 26, 2025source: clinicaltrials